HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 65833Erstellt: 2. November 2026
Milnacipran
Fetzima · Levomeprazole · levomilnacipran · Dextromilnacipran · Dextromilnacipran, 10 mM in DMSO · Dextromilnacipran，Levomilnacipran，F 2696 · TIANFU-CHEM CAS NO.96847-55-1 Levomilnacipran · (1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
https://huagongshe.com/de/chemical/65833
Identifikatoren & physikalische Daten
| CAS No. | 92623-85-3 |
|---|
| Summenformel | C15H22N2O |
|---|
| Durchschnittliche Molmasse | 246,35 g/mol |
|---|
| Monoisotopische Masse | 246,17321333 g/mol |
|---|
| SMILES | CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN |
|---|
| InChIKey | GJJFMKBJSRMPLA-HIFRSBDPSA-N |
|---|
| PubChem CID | 65833 |
|---|
| ChEMBL | CHEMBL252923 |
|---|
| ChEBI | CHEBI:94468 |
|---|
| DTXSID | DTXSID3048287 |
|---|
Chemische & physikalische Eigenschaften
| XLogP | 1,4 |
|---|
| Polarare Oberfläche (TPSA) | 46,3 |
|---|
| H-Brücken-Donoren | 1 |
|---|
| H-Brücken-Akzeptoren | 2 |
|---|
| Frei drehbare Bindungen | 5 |
|---|
| Schwere Atome | 18 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 295 |
|---|
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
|---|
| Löslichkeit | 1.23e+00 g/L |
|---|
| Human Drugs | Antidepressants -> Serotonin-noradrenaline reuptake inhibitors (SNRI)Breast FeedingLactationMilk, HumanAntidepressive AgentsSerotonin and Noradrenaline Reuptake Inhibitors |
|---|
| Schmelzpunkt | 179°C |
|---|
| Physical Description | Solid |
|---|
| Collision Cross Section | 149.3 Ų [M-NH2]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: Antidepressants] |
|---|
| Siedepunkt | 393.0±21.0 °C(Predicted) |
|---|
| Dichte | 1.077 |
|---|
| pKa (Säurekonstante) | 10.36±0.29(Predicted) |
|---|
| Aggregatzustand | Liquid |
|---|
| Farbe | Colorless to light yellow |
|---|
Sicherheit & Vorschriften
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)milnacipranDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022 |
|---|
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
|---|
